USD 5.6B of investments into Lifesciences startups in September’20

We recorded 96 VC/PE transactions pertaining to the global life sciences sector for Sep 2020, aggregating to a sum of USD 5.6B. USA recorded 52 transactions for with total investment of USD 2.6B. China reported investment of USD 1.5B over 16 VC/PE transactions. China also reported 2 IPOs aggregating to…

Read More

China’s lifescience sector receives more VC/PE investment in Aug’20 compared to the USA

Aug’20 saw China’s lifescience sector receive more VC/PE investment than the USA for the second time ever in terms of monthly recorded amounts, with the first instance being in Apr’20. For Aug’20, China reported USD 2024m of venture capital investments, as compared to USD 1531m recorded by the USA. China…

Read More

July was a landmark month for Chinese Biotech

China’s biotech sector continues to blossom as far as fund raising goes. For 4 months in a row, the sector is witnessing increasing amounts of fund raise. While private deals (VC/PE) led the increase in April and May, in June and July, it is public market fund raising that drove…

Read More

China’s Booming Biotech IPOs

We have earlier commented on the sharply accelerated venture capital activity in the biotech sector in China. From around 2-3 deals a month, aggregating maybe USD100m 2-3 years ago, China is now witnessing close to USD1B of venture capital investments in biotech sector on a  monthly basis. Keeping company is…

Read More

Covid-19 vaccine pipeline expands to 13 at clinical stage

Furious activity is on around the world to come up with a vaccine for the Covid-19 virus. The stakes are high, not just in human life saving imperative, but also likely financial rewards to the company that is first off the block. The active pipeline, as document by the World…

Read More

China’s monthly biotech investments headed towards USD1B+ consistently

Earlier this week we wrote how on 2 consecutive months, China’s biotech sector had witnessed more than USD1B of venture capital investment. That chart ignored another source of risk capital – IPOs. China has been producing around 1 biotech IPO a month consistently. These are typically pre-revenue R&D companies, but…

Read More

China’s supercharged biotech investment momentum continues in May’20

For the second month in a row, China’s biotech companies attracted more than USD1B of venture capital investment. Biotech investments crossed USD1B for the first time in April’20. Hence, May is the second consecutive month where VC/PE investments in biotech have crossed USD1B. In terms of amout invested, China inching…

Read More